양세훈 교수 연구실
article|
인용수 7
·2023
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
Jehun Kim, Tae Won Jang, Chang‐Min Choi, Mi‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong‐Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
IF 4Translational Lung Cancer Research
초록
First-line afatinib in the real-world setting showed clinically meaningful effectiveness in patients with <i>EGFR</i>-mutant NSCLC and BM. CNS failure was a poor prognostic factor for TOT and OS correlating with younger age, poor ECOG PS, higher metastatic number, advanced disease stage, uncommon <i>EGFR</i> mutations, and baseline liver and/or bone metastases.
키워드
AfatinibMedicineInternal medicineBrain metastasisOncologyProportional hazards modelLung cancerCumulative incidenceMetastasisMultivariate analysis